Edition:
United States

Aveo Pharmaceuticals Inc (AVEO.OQ)

AVEO.OQ on NASDAQ Stock Exchange Capital Market

3.00USD
16 Feb 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.00
Open
$2.98
Day's High
$3.05
Day's Low
$2.92
Volume
574,940
Avg. Vol
324,007
52-wk High
$4.24
52-wk Low
$0.50

Chart for

About

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI)... (more)

Overall

Beta: 1.33
Market Cap(Mil.): $354.92
Shares Outstanding(Mil.): 118.31
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Aveo Pharmaceuticals ‍Entered Into Sales Agreement With Leerink Partners

* AVEO PHARMACEUTICALS SAYS ‍ENTERED INTO A SALES AGREEMENT WITH LEERINK PARTNERS - SEC FILING

Feb 16 2018

BRIEF-AVEO Says EUSA Pharma Granted Positive NICE Recommendation For Fotivda

* AVEO ANNOUNCES EUSA PHARMA GRANTED POSITIVE NICE RECOMMENDATION FOR FOTIVDA® (TIVOZANIB) AS FIRST LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA

Feb 12 2018

Ex-Aveo Pharmaceuticals exec avoids max penalty in SEC fraud case

A federal magistrate judge on Friday ordered the former chief medical officer of Aveo Pharmaceuticals Inc to pay a $50,000 penalty, a third of what the U.S. Securities and Exchange Commission requested, to resolve civil fraud charges.

Feb 09 2018

SEC seeks penalty, 5-year ban for ex-Aveo Pharmaceuticals exec

The U.S. Securities and Exchange Commission is pushing to have the former chief medical officer of Aveo Pharmaceuticals Inc pay a $150,000 penalty and be barred for five years from serving as an officer or director of a public company for committing fraud.

Jan 02 2018

Aveo settles investor lawsuit over cancer drug for $15 mln, warrants

Aveo Pharmaceuticals Inc will settle claims it misled shareholders about the Food and Drug Administration's concerns regarding a kidney cancer drug it was developing by paying $15 million out of insurance and issuing warrants for affected investors to buy 2 million shares.

Dec 27 2017

BRIEF-Aveo Pharma Entered Into Binding MoU With Class Representatives Regarding Settlement Of A 2013 Class Action Lawsuit

* AVEO PHARMACEUTICALS - ENTERED INTO BINDING MOU WITH CLASS REPRESENTATIVES BOB LEVINE & WILLIAM WINDHAM REGARDING SETTLEMENT OF A 2013 CLASS ACTION LAWSUIT

Dec 26 2017

BRIEF-Aveo Oncology Announces Clinical Updates To Tivozanib And Ficlatuzumab Programs

* AVEO ONCOLOGY ANNOUNCES CLINICAL UPDATES TO TIVOZANIB AND FICLATUZUMAB PROGRAMS

Dec 07 2017

BRIEF-Aveo Pharmaceuticals Files For Mixed Shelf Of Upto $200 Mln

* AVEO PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING Source text: [http://bit.ly/2Bzw8T1] Further company coverage:

Nov 30 2017

Ex-Aveo Pharmaceuticals CEO settles SEC fraud claims

Aveo Pharmaceuticals Inc's former chief executive has agreed to settle a lawsuit by the Securities and Exchange Commission claiming he misled investors about the biotech company's efforts to obtain regulatory approval for a drug to treat kidney cancer.

Nov 20 2017

BRIEF-AVEO PHARMACEUTICALS REPORTS Q3 LOSS PER SHARE $0.22

* AVEO REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Nov 07 2017

Competitors

Earnings vs. Estimates